Cancer-related venous thromboembolism: Insight into underestimated risk factors

Hematology/ Oncology and Stem Cell Therapy

Volumn 3, Issue 4, 2010, Pages 191-195

  Al Diab, Abdurrahman I ^a  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ERYTHROPOIETIN; HEMOGLOBIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADOLESCENT; ADULT; AGE; AGED; ANEMIA; ARTICLE; CANCER PATIENT; CANCER STAGING; CENTRAL VENOUS CATHETER; DEEP VEIN THROMBOSIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OUTCOME ASSESSMENT; PERFORMANCE; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

EID: 79952024334     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.5144/1658-3876.2010.191     Document Type: Article

References (28)

1. Donati MBMB. Cancer and thrombosis. Haemostassis 1994; 24:128-131.
2. Furie B, Furie BC: Mechanisms of thrombus formmation. N Engl J Med 359:938-949, 2008.
3. Constanti V, Zacharski LRLR, Moritz TE et al. The platelet count in carcinoma of the lung and colon. Thromb Haemost 1990; 64:501-505.
4. Saphner T, Tormey DC, Gray R. Venous and arterrial thrombosis in patients who received adjuvant chemotherapy for breast cancer. J Clin Oncol 1991; 9:286-294.
5. Goodnough LT, Saito H, Manni A et al. Increased incidence of thrombosis in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 1984; 54:1264-1268.
6. Clahsen PC, Cornelis JH, Julien J-P et al. Thrombboembolic complications after perioperative chemmotherapy in women with early breast cancer: a EORTC Breast Cancer Cooperative group study. J Clin Oncol 1994; 12:1266-1271.
7. Levine MNMN, Gent M, Hirsh J et al. The thromboggenic effect of anticancer drug therapy in women with stage IIII breast cancer. N Engl J Med 1988; 318:404-407.
8. Wall JG, Weiss RW, Norton L et al. Arterial thrombosis associated with adjuvant chemotheraapy for breast cancer: a Cancer and Leukemia Group B study. Am J Med 1989; 87:501-504?
9. Tricot GJ, Lauer RC, Appelbaum FR, et al. Manaagement of the myelodysplastic syndrome. Semin Onc 1987; 14:444-53.
10. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovvasc Res 2003; 59:538-48.
11. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analyssis of 205 patients from 17 studies. Br J Haematol 1995; 89:67-71.
12. Bohlius J, Wilson J, Seidenfeld J, et al: Recombbinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708-714, 2006.
13. Levine M, Hirsh J, Gent M et al. Double blind randomised trial of very-low-dose warfarin for the prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343:886-889.
14. Lyman GH, Khorana AAAA, Falanga A, et al: American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505, 2007.
15. Kakkar AK, Levine M, Pinedo HM, et al: Venous thrombosis in cancer patients: Insights from the FRONTLINELINELINELINE survey. Oncologist 8:381-388, 2003.
16. Geerts WH, Bergqvist D, Pineo GF, et al: Prevvention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (ed 8). Chest 133:381S-453S, 2008 (suppl).
17. Wagman LDLD, Baird MF, Bennett CL, et al: Vennous thromboembolic disease: NCCN Clinical practice guidelines in oncology. J Natl Compr Canc Netw 6:716-753, 2008.
18. Debourdeau P, Farge-Bancel D, Bosquet L, et al: 2008 Standards, options: Recommendations for venous thromboembolic events (VTE) treatment and central venous catheter thrombosis (CVCT) management in cancer patients. Bull Cancer 95:750-761, 2008.
19. Mandala M, Falanga A, Roila F: Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 19: ii126-ii127, 2008 (suppl 2).
20. Khorana AAAA, Francis CW, Culakova E, et al: Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24:484-490, 2006.
21. Khorana AAAA, Francis CW, Culakova E, et al: Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherappy. J Thromb Haemost 5:632-634, 2007.
22. Chew HK, Wun T, Harvey DJ, et al: Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 25:70-76, 2007.
23. Dr Nalluri. Risk of Venous Thromboembolism with Bevacizumab in Cancer Patients. JAMAAMAAMA Vol. 301 No. 14, April 8, 2009.
24. Kuderer NMNM, Francis CW, Culakova E, et al: E. Venous thromboembolism represents a major risk factor for early all-cause mortality in patients receiving cancer chemotherapy. J Clin Oncol 26:506s; 2008 abstr 9521.
25. Moore FD, Osteen RT, Karp DDDD et al. Anticoaagulants, venous thomboembolis, and the cancer patient. Arch Surg 1981; 116:405-407.
26. Clarke-Pearson DLDL, Synan IS, Creasman WT. Anticoagulation therapy for venous thromboembbolism in patients with gynecologic malignancy. Am J Obstet Gynecol 1983; 147:347-369.
27. Martins RG, Colowick ABAB, Ewenstein BMBM et al. Anticoagulation in cancer patients with venous thromboembolic disease. Blood 1997; 909(suppl 1):297a.
28. Sorensen HT, Mellemkjaer L, Olsen JH, et al: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846-1850, 2000.